Monday, August 24, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· May 21, 2026

Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

View original at globenewswire.com
Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting ASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestina…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Development strategy combining ASCEND and planned ADC combination studies is intended to rapidly expand understanding of CR-001 across multiple solid tumor types, beginning with initial data expected in Q1 2027

    60% confidence

  • Proof-of-concept clinical data from ASCEND including initial safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity from dose escalation and backfill cohorts anticipated in Q1 2027

    60% confidence

  • CR-001 is designed to serve as an immuno-oncology backbone and best-in-class PD-1 x VEGF bispecific antibody for people living with cancer

    60% confidence

  • The first Phase 1/2 ADC combination trial with CR-001 is expected to initiate in the second half of 2026

    60% confidence

  • Strong global investigator engagement in ASCEND underscores the unmet need in cancer treatment and the study's efficient design to evaluate CR-001 as monotherapy and in combination with standard-of-care therapies

    60% confidence

  • Initial data from Phase 1/2 trial in China of CR-001 in combination with a Kelun-Biotech ADC anticipated in mid-2027 (Q2/Q3)

    60% confidence

  • In preclinical studies, CR-001 demonstrated cooperative pharmacology with increased binding to PD-1 and signal blockade in the presence of VEGF, as well as robust antitumor activity

    60% confidence

  • Initial data of CR-001 in combination with standard of care chemotherapy from ASCEND dose expansion cohorts anticipated in mid-2027 (Q2/Q3)

    60% confidence

  • Kelun-Biotech plans to initiate a Phase 1/2 trial of CR-001 (SKB118) in China in the first half of 2026

    60% confidence

  • ASCEND trial is expected to enroll up to 290 patients across dose-escalation, backfill, and dose-optimization cohorts at centers in the United States, Europe, and Asia Pacific

    60% confidence

  • CR-001's anti-VEGF activity may normalize the vasculature at the tumor site, potentially improving the localization and effectiveness of combination therapies such as ADCs

    60% confidence

Cited in these Via News reports